IgM multiple myeloma: diagnostic difficulties and results of bortezomib treatment – case report

• Authors: Rafał Machowicz , Kamila Skwierawska , Krzysztof Mądry , Michał Górka , Jagoda Żurawska , Piotr Kacprzyk , Anna Waszczuk-Gajda , Jadwiga Dwilewicz-Trojaczek
• Languages of publication: EN

Abstracts

EN

The IgM paraprotein secretion is most frequently associated with Waldenström’s macroglobulinemia. In very rare cases it may also occur in multiple myeloma. The diagnostic and therapeutic process of a 84 year old male suffering from IgM multiple myeloma is described, including difficulties in establishing this diagnosis. Due to infectious complications, after the first cycle of melphalan– prednisone–bortezomib treatment, melphalan was stopped, subsequently, bortezomib and prednisone doses were also reduced. Two treatment interruptions have occurred. Despite reduced treatment intensity, the patient was in very good partial remission, while the toxicity profile was acceptable. IgM multiple myeloma should be included in the differential diagnosis of IgM paraproteinemia, also when osteolytic lesions and translocation 11:14 are not detected. Bortezomib-based therapy can be effective in elderly patients (also in those suffering from cardiac insufficiency), even when dose reduction is required.

Keywords

EN

IgM; Waldenström’s macroglobulinemia; bortezomib; multiple myeloma

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Education
• Journal: OncoReview
• Year: 2014
• Volume: 4
• Issue: 4
• Pages: A160-A164

Contributors

author

Rafał Machowicz

• Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw

author

Kamila Skwierawska

• Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw

author

Krzysztof Mądry

• Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw

author

Michał Górka

• Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw

author

Jagoda Żurawska

• Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw

author

Piotr Kacprzyk

• Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw

author

Anna Waszczuk-Gajda

• Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw

author

Jadwiga Dwilewicz-Trojaczek

• Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw

References

• Dmoszyńska A, Walter-Croneck A, Usnarska-Zubkiewicz L et al. Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2013. Acta Haematol Pol 2013; 44(1): 43-47.
• Jurczyszyn A, Skotnicki AB. Szpiczak mnogi – kompleksowa diagnostyka i terapia. Górnicki Wydawnictwo Medyczne, Wrocław 2010.
• Lech-Marańda E. Makroglobulinemia Waldenströma/chłoniak limfoplazmocytowy. W: Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych – pp. 2013 rok. Krzakowski M, Warzocha K (ed.). Via Medica, Gdańsk 2013.
• Schuster SR, Rajkumar SV, Dispenzieri A et al. IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom’s macroglobulinemia. Am J Hematol 2010; 85(11): 853-855.
• Higeta D, Yokohama A, Osaki Y et al. IgM-lambda multiple myeloma presenting with systemic amyloidosis. Rinsho Ketsueki 2009; 50(12): 1711-1714.
• Willenbacher E, Erdel M, Strasser U et al. IgM myeloma: more on a rare entity. Br J Haematol 2008; 143(1): 146-148.
• Fan J, Fu W, Shi H et al. Clinical and laboratory features of four cases with IgM multiple myeloma. Zhonghua Xue Ye Xue Za Zhi 2013; 34(4): 341-344.
• Lin P, Hao S, Handy BC et al. Lymphoid neoplasms associated with IgM paraprotein: a study of 382 patients. Am J Clin Pathol 2005; 123(2): 200-205.
• Feyler S, O’Connor SJM, Rawstron AC et al. IgM myeloma: a rare entity characterized by a CD20-CD56-CD117-immunophenotype and the t(11;14). Br J Haematol 2008; 140(5): 547-551.
• An G, Xu Y, Shi L et al. T(11;14) Multiple Myeloma: a Subtype Associated With Distinct Immunological Features, Immunophenotypic Characteristics But Divergent Outcome. Leuk Res 2013; 37(10): 1251-1257.

• Document Type: article